Jane S. Ricciuti, RPh, MS


November 29, 2004

In This Article

Central Nervous System Agents

(sumatriptan) Nasal Spray

Manufacturer: GlaxoSmithKline

Drug Approval Classification: Supplemental New Drug Application (Approval Date: 10/13/04)

New Indication: This supplemental new drug application proposes the use of Imitrex (sumatriptan) nasal spray for the acute treatment of migraine in adolescents.

Imitrex (sumatriptan) Nasal Spray Labeling

Imitrex (sumatriptan) Nasal Spray


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.